Tags Archive Navigation
icon
-
Media ReleaseCosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditions
-
Media ReleaseNovartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
-
Media ReleaseNovartis receives European Commission approval for Tabrecta® for the treatment of METex14 skipping advanced non-small cell lung cancer
-
Media ReleaseNovartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
-
Media ReleaseNew Novartis data show Piqray® effectiveness across key biomarkers in patients with HR+/HER2- metastatic breast cancer
-
Media ReleaseNew CDK4/6i data at ASCO reinforce Novartis Kisqali® as only drug in class with consistently proven overall survival benefit in HR+/HER2- metastatic breast cancer
-
Media ReleaseNovartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
-
Media ReleaseNovartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
-
Media ReleaseNew Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
-
Media ReleaseNovartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
-
Media ReleaseNovartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten
-
Media ReleaseNovartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 28
- › Next page